This is a working overview of GHRH analogue, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-23. Anything still debated is marked as such rather than presented as settled.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility | Soluble in water | Consistent with peptide nature |
| Typical storage | 2 to 8 degrees Celsius | Refrigerated, dry, protected from light |
| Common analytical method | Reversed-phase HPLC | Purity and impurity profiling |
| Identity confirmation | Mass spectrometry | Molecular mass verification |
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
According to the Israel Central Bureau of Statistics (CBS), in 2021 the ethnic makeup of the city was 99 percent Jewish and others, without significant Arab population. As of March 2021 the city numbered 53,595 persons, with a high percentage of young people: 37% of the population was in the 0–19 age group and 71% of the total population was younger than 44.
== Structure == The active bifunctional enzyme of trypanothione synthase is found as a 74.4 KDa monomer consisting of 652 residues with two catalytic domains. Its C-terminal domain is a synthetase and has an ATP-grasp family fold that is usually found in carbon-nitrogen ligases. The N-terminal domain is a cysteine, histidine-dependent aminohydrolase amidase. Structurally the synthetase and amidase domains are bound together by three residues of Glu-650-Asp-651-Glu-652 through hydrogen bonding and salt bridge interactions with basic side chains in order for the protein to properly fold. These three residues also block the catalytic Cys-59 in the amidase domain. It is currently known that the synthetase active site is shaped in the fashion of a triangular cavity that binds the three substrates such that the end of each molecule is nestled in a vertex of the triangle. The particular residues of Arg-553 and Arg-613 have been found to key for synthetic function, however further research into the structure of trypanothione synthase must be done in order to fully understand the enzyme's active sites.
== Regulation of mRNA stability == Pin1, a parvulin, regulates mRNA stability and expression in certain eukaryotics mRNAs. These mRNAs are GM-CSF, Pth, and TGFβ and each of them have AREs, or AU-rich cis-elements. The ARE binding protein KSRP has a Pin1 binding site. Pin1 binds to this site and dephosphorylates the serine and isomerizes the peptide bond between Ser181 and Pro182. This isomerization causes the decay of Pth mRNA. KSRP, and other ARE binding proteins like AUF1, are thought to affect the other mRNAs through mechanisms similar to Pth, with the requirement of a phosphorylated serine bonded to a proline in a specific conformation. Pin1 also triggers proline isomerization of Stem-Loop Binding Protein (SLBP), allowing it to control the dissociation of SLBP from histone mRNA. This leads to Pin1 being able to affect histone mRNA decay. Pin1 affects many other genes in the form of gene silencing through the disruption of cell pathways, making it important in mRNA turnover by modulating RNA binding protein activity.
https://web.archive.org/web/20070405211049/http://www.dentistry.leeds.ac.uk/biochem/MBWeb/mb1/part2/krebs.htm#animat1 - animation of the general mechanism of the PDC (link on upper right) at University of Leeds Pyruvate+Dehydrogenase+Complex at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
== Lineage == Constituted 5 July 1942 in the Army of the United States as the 2d Company, 1st Battalion, First Regiment, 1st Special Service Force, a combined Canadian-American organization Activated on 9 July 1942 at Fort William Henry Harrison, Montana Disbanded on 6 January 1945 in France Reconstituted on 15 April 1960 in the Regular Army; concurrently consolidated with Company B, 1st Ranger Infantry Battalion (activated 19 June 1942), and consolidated unit redesignated as Headquarters and Headquarters Company, 1st Special Forces Group, 1st Special Forces Consolidated on 30 September 1960 with Headquarters and Headquarters Company, 1st Special Forces Group (constituted 14 June 1957 in the Regular Army and activated 24 June 1957 in Japan), and the consolidated unit was designated as Headquarters and Headquarters Company, 1st Special Forces Group, 1st Special Forces (organic units concurrently constituted and activated 4 October 1960) Group inactivated 30 June 1974 at Fort Bragg, North Carolina Activated 1 September 1984 at Fort Lewis, Washington (Former Company B, 1st Ranger Infantry Battalion, withdrawn 3 February 1986, consolidated with Company N, 75th Infantry, and consolidated unit redesignated as Company N, 75th Ranger Regiment – hereafter separate lineage) Redesignated 1 October 2005 as the 1st Special Forces Group, 1st Special Forces Regiment
The synoptic condition for the Tehuantepecer, a violent mountain-gap wind in between the mountains of Mexico and Guatemala, is associated with high-pressure system forming in Sierra Madre of Mexico in the wake of an advancing cold front, which causes winds to accelerate through the Isthmus of Tehuantepec. Tehuantepecers primarily occur during the cold season months for the region in the wake of cold fronts, between October and February, with a summer maximum in July caused by the westward extension of the Azores-Bermuda high pressure system. Wind magnitude is greater during El Niño years than during La Niña years, due to the more frequent cold frontal incursions during El Niño winters. Tehuantepec winds reach 20 knots (40 km/h) to 45 knots (80 km/h), and on rare occasions 100 knots (190 km/h). The wind's direction is from the north to north-northeast. It leads to a localized acceleration of the trade winds in the region, and can enhance thunderstorm activity when it interacts with the Intertropical Convergence Zone. The effects can last from a few hours to six days. Between 1942 and 1957, La Niña had an impact that caused isotope changes in the plants of Baja California, and that had helped scientists to study his impact.
Litvinenko in 2006, and was suspected as a possible cause of Yasser Arafat's death, following exhumation and analysis of his corpse in 2012–2013. The radioisotope may also have been used to kill Yuri Shchekochikhin, Lecha Islamov and Roman Tsepov.
Sources: en.wikipedia.org
Ambulatory care pharmacy (BCACP) Critical care pharmacy (BCCCP) Nuclear pharmacy (BCNP) Nutrition support pharmacy (BCNSP) Oncology pharmacy (BCOP) Pediatric pharmacy (BCPPS) Geriatric pharmacy (BCGP) Pharmacotherapy (BCPS) Infectious disease pharmacy (BCIDP) Compounded sterile preparations pharmacy (BCSCP) Cardiology pharmacy (BCCP) Emergency medicine pharmacy (BCEMP) Transplant Pharmacist (BCTXP) Psychiatric pharmacy (BCPP) There are several types of clinical pharmacists in the United States. In California they are called advanced practice pharmacists (APh). In New Mexico, they are known as Pharmacist Clinicians (PhC) and lastly in Montana and North Carolina they are known as Clinical Pharmacist Practitioners (CPP). Clinical pharmacists in the Veteran Administration are known as Clinical Pharmacy Specialists (CPS). Role in the health care system Within the system of health care, clinical pharmacists are experts in the therapeutic use of medications. They routinely provide medication therapy evaluations and recommendations to patients and other health care professionals. Clinical pharmacists are a primary source of scientifically valid information and advice regarding the safe, appropriate, and cost-effective use of medications. Clinical pharmacists are also making themselves more readily available to the public. In the past, access to a clinical pharmacist was limited to hospitals, clinics, or educational institutions.
=== Inside the continental crust === The continental crust, with tectonic fault zones could present a stable and well-protected environment for long-term prebiotic evolution. Inside these systems of cracks and cavities, water and carbon dioxide present the bulk solvents. Their phase state could vary between liquid, gaseous and supercritical, depending on pressure and temperature. When forming two separate phases, the system provides optimal conditions for phase transfer reactions. Concurrently, the contents of the tectonic fault zones are supplied with inorganic educts (e.g. carbon monoxide, hydrogen, ammonia, hydrogen cyanide, nitrogen, and phosphate) and simple organic molecules (e.g. amino acids, long-chain amines, fatty acids, long-chain aldehydes). Part of the tectonic fault zones is at a depth of around 1000 m. For carbon dioxide, it provides temperature and pressure conditions near the phase transition point between the supercritical and the gaseous state. This allows lipophilic organic molecules that dissolve well in supercritical CO2 to accumulate, leading to local precipitation. Periodic pressure variations such as caused by geysers or tidal influences result in periodic phase transitions, keeping the local reaction environment in a constant non-equilibrium state. In presence of amphiphilic compounds (such as the long chain amines and fatty acids), subsequent generations of vesicles are formed that are selected for their stability.
==== Food ==== In 2018, world production of poppy seeds for consumption was 76,240 tonnes, led by Turkey with 35% of the world total (table). Poppy seed production and trade are susceptible to fluctuations mainly due to unstable yields. The performance of most genotypes of Papaver somniferum is very susceptible to environmental changes. This behaviour led to a stagnation of the poppy seed market value between 2008 and 2009 as a consequence of high stock levels, bad weather and poor quality. The world leading importer of poppy seed is India (16 000 tonnes), followed by Russia, Poland and Germany. Poppy seed oil remains a niche product due to the lower yield compared to conventional oil crops.
Sources: en.wikipedia.org
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.
Reversed-phase high-performance liquid chromatography is commonly used to separate and quantify the peptide and its impurities. Mass spectrometry is often paired with it to confirm identity. Together they provide a profile of related substances.
Extreme pH values accelerate hydrolytic degradation of the peptide backbone. Buffered solutions in a near-neutral range generally slow this process. Solution age and temperature also affect the rate of breakdown.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.